The Rani platform is capable of delivering orally any payload, including proteins, peptides, and antibodies, to which could help millions of patients fight their disease in a wide range of therapeutic areas.

6 days ago · Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill ® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of ...

6 days ago · Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs.

Feb 5, 2025 · Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United...

Rani is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe will have the potential to transform medicine and improve patient outcomes.

RT-105 is the original RaniPill capsule containing a TNF-α inhibitor antibody for the treatment of psoriatic arthritis. Several TNF-alpha antibodies, such as adalimumab, have been approved by the FDA and EMA to treat a range of autoimmune conditions, including psoriasis, rheumatoid arthritis and Crohn’s disease.

Rani Therapeutics has developed a disruptive technology for the oral delivery of biologics. The RaniPill® Capsule is an innovative robotic pill that moves fully intact through the stomach, where acids typically break down drugs, and then reaches the intestine, where it delivers the drug via transenteric injection.

Jun 24, 2024 · Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has tested 15 molecules in the RaniPill® platform.

Rani Therapeutics also announced its anticipation for a Phase 1 clinical trial in 2025 for RT-114, an oral GLP-1/GLP-2 dual agonist for obesity treatment, developed in partnership with ProGen.